Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Effects on heart rate

This article was originally published in The Tan Sheet

Executive Summary

Energy drinks, most of which contain high levels of caffeine and amino acid taurine, increase blood pressure and heart-rate levels, according to results of Wayne State (Mich.) University research. Over the duration of the study, subjects' heart rates increased five to seven beats per minute and systolic blood pressure increased 10 mmHg. "Individuals with high blood pressure and heart disease should be advised to avoid these drinks," says James Kalus, pharmacist and senior manager of patient care services at Henry Ford Hospital in Detroit. While the product used in the study had as much caffeine as one to two cups of coffee, others contain "much higher levels," said Kalus. Researchers are unsure what effect exercise or combining the products with alcohol has on users, but several state attorneys general concerned with health claims in alcoholic-energy-drink advertising are calling for greater federal enforcement against the practice (1"The Tan Sheet" Sept. 3, 2007, p. 14)...

You may also be interested in...

State Officials Seek To Drain Health Claims From Alcoholic Energy Drink Ads

Several state attorneys general concerned with health-related statements in alcoholic energy drink advertising designed to attract young people are calling for greater federal enforcement against the practice

Long Hot Summer For Novel Drug Reviews Forecast At US FDA

Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.

Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza

The latest drug development news and highlights from our US FDA Performance Tracker.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts